Latest Intellectual Property News

Holista Colltech has inked a binding supply and development agreement with US-based Regenerex Pharma to exclusively supply proprietary ovine collagen for advanced wound care products, targeting the lucrative US market initially with plans for global expansion.

Acusensus Limited reported a 20% increase in revenue to $59.35 million for FY25, driven by new and expanded contracts across Australia, New Zealand, the US, and the UK. However, net losses widened by 72.3%, reflecting higher operating expenses and ongoing litigation costs.

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Locksley Resources has partnered with Rice University to pioneer domestic antimony processing in the US, aiming to reduce reliance on foreign supply and support critical defense and energy sectors.

InhaleRx Limited reported a widening half-year loss as it accelerates clinical trials for inhaled drug-device therapies, supported by a substantial $38.5 million funding facility.

Rubicon Water Limited posted its strongest revenue since IPO at $69.1 million in FY25, driven by robust growth in the US and EMEA markets. Despite a $7 million net loss, the company improved cash flow and reduced debt, positioning itself for further global irrigation automation expansion.

Carnegie Clean Energy reported a $2.33 million net loss for FY2025 but made significant strides in commercialising its wave energy technologies, supported by new loans and a US subsidiary launch.

INOVIQ Limited reported a $6.9 million net loss for FY25 while making significant strides in its exosome-based cancer diagnostics and therapeutics pipeline, including a breakthrough ovarian cancer screening test and promising CAR-exosome therapy results.

Carbonxt Group Limited has announced a fully underwritten non-renounceable entitlement offer of Loyalty Options to eligible shareholders, aiming to raise approximately $697,772 to support its new Activated Carbon manufacturing facility in Kentucky. The offer provides shareholders with one Loyalty Option for every six shares held, exercisable at $0.07 within three years.

EOS has reported a 126% increase in its contract backlog to $307 million in 1H 2025, driven by strong demand for its defence and space technologies despite a revenue decline. The company secured a landmark €71.4 million high energy laser weapon export contract and continues to strengthen its balance sheet.

Arovella Therapeutics reported a 14% reduction in net loss to $7.5 million for FY25, bolstered by a $15 million capital raise to fund its lead iNKT cell therapy program progressing toward a pivotal phase 1 clinical trial.